BRIEF-Proqr Announces Positive Phase 1 Target Engagement Data For Ax-0810, Establishing First Clinical Validation Of The Axiomer Rna Editing Platform

ProQR Therapeutics N.V.

ProQR Therapeutics N.V.

PRQR

0.00

June 25 (Reuters) - ProQR Therapeutics NV PRQR.O:

  • PROQR ANNOUNCES POSITIVE PHASE 1 TARGET ENGAGEMENT DATA FOR AX-0810, ESTABLISHING FIRST CLINICAL VALIDATION OF THE AXIOMER RNA EDITING PLATFORM

  • PROQR THERAPEUTICS NV - AX-810 SHOWS FAVORABLE SAFETY PROFILE AND EIGHT-WEEK HALF-LIFE

  • PROQR THERAPEUTICS NV - AX-2911 FIRST-IN-HUMAN IIT IN CHINA EXPECTED FIRST HALF 2027

  • PROQR THERAPEUTICS NV - AX-422 CTA FILING FOR MPS1 EXPECTED EARLY 2027 WITH INITIAL DATA FIRST HALF 2027

  • PROQR THERAPEUTICS NV - PHASE 2 PROGRAM EXPECTED TO START MID-2027 WITH INTERIM DATA BY MID-2028

Source text: ID:nGNX7mH6gl

Further company coverage: PRQR.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.